Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients
Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022
Tumour agnostic treatments in GI cancer
Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC